AZ Will Sideline ‘Lucky Mistake’ To Secure COVID-19 Vaccine Approval

US Unlikely To Accept Data

A lower first dose boosted the vaccine’s efficacy result – but AstraZeneca has conceded this has to be proven in a separate trial.

Jenner Institute by John Cairns
UK regulator the MHRA is to review the core data - but the FDA is likely to wait for US trial data. • Source: John Cairns for Jenner Institute

More from Business

More from Scrip